Sci Rep:突破!利用CRISPR-Cas9技术开发出帕金森疾病新型筛选工具

2017-06-07 生物谷 生物谷

近日,一项发表在国际杂志Scientific Reports上的研究报告中,来自中佛罗里达大学(University of Central Florida)的研究人员通过研究利用突破性的基因编辑技术开发出了一种帕金森疾病的新型筛查工具,帕金森疾病是一种严重的神经系统疾病,这种技术能够帮助科学家们在实验室中对名为α-突触核蛋白的大脑蛋白进行实

近日,一项发表在国际杂志Scientific Reports上的研究报告中,来自中佛罗里达大学(University of Central Florida)的研究人员通过研究利用突破性的基因编辑技术开发出了一种帕金森疾病的新型筛查工具,帕金森疾病是一种严重的神经系统疾病,这种技术能够帮助科学家们在实验室中对名为α-突触核蛋白的大脑蛋白进行实时监测,这种蛋白和帕金森疾病发病直接相关。

图片来源:UCF, College of Medicine

研究者Levi Adams说道,正常情况下,α-突触核蛋白存在于大脑中,但由于某些原因,有时候机体帕金森的水平会处于异常状态,因此如果我们能够对细胞中α-突触核蛋白的水平进行实时监测的话,我们就能够鉴别出引发这种蛋白水平异常的原因,并且采取措施及时应对。研究人员认为,本文研究工作对于后期开发治疗帕金森疾病的新型靶向性疗法非常关键。

文章中,研究人员利用CRISPR-Cas9基因编辑技术进行研究,这种系统是科学家们近年来使用最为广泛的生物医学工具,其能够帮助科学家对植物和动物机体中的DNA进行精准化修饰,同时还不会杀灭正常细胞,如今这种新型的基因编辑系统慢慢地开始被研究人员用来开发治疗癌症和帕金森等疾病的新型疗法了。

CRISPR-Cas9基因编辑技术能够对活体细胞中的DNA进行改变,同时其在不杀灭细胞的情况下还能够实时对基因表达进行监测,如果没有这种新型基因编辑技术,我们可能会从细胞中提取出所有的蛋白质来对其测定,这无疑会对细胞产生杀灭作用。这项研究中,研究者Burnett及其同事利用CRISPR技术对α-突触核蛋白基因进行了编辑,并且在该基因中插入了一种荧光标记,每当细胞开始产生α-突触核蛋白时,荧光标记就会发光;而这种反应就能够被研究者们轻松观察到,研究者Adams说道,发光越多就意味着α-突触核蛋白的水平增加越明显,这时候我们就要考虑是否个体已经处于疾病状态了。

研究者发现,对光进行测定时一种测定α-突触核蛋白产量的可靠方法;如果利用特殊药物来处理任何一个被修饰的细胞,如果细胞不再产生荧光,那就意味着这种药物或许能够用来治疗疾病。对细胞进行工程化修饰后,研究者就能够对新型和当前已经存在的药物进行筛选来观察期如何调节患者机体中α-突触核蛋白的水平。

未来研究人员希望能够通过更为深入的研究鉴别出新方法来降低α-突触核蛋白的产生,从而有效抑制帕金森疾病的发生和进展;本文研究中研究者重点对帕金森疾病发生期间α-突触核蛋白如何杀灭神经元进行了深入研究。

原始出处:

Sambuddha Basu, Levi Adams, Subhrangshu Guhathakurta, et al. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3′end using CRISPR-Cas9 genome editing technique. Scientific Reports  (2017) doi:10.1038/srep45883

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 yuandd
  2. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 respect
  4. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 yaanren
  8. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 liusanxin

    是挺新颖的,可行性大吗

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1276031, encodeId=4aec12e603143, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360439, encodeId=f1e81360439ee, content=<a href='/topic/show?id=99e5521532' target=_blank style='color:#2F92EE;'>#CRISPR-Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5215, encryptionId=99e5521532, topicName=CRISPR-Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365044, encodeId=85a11365044a8, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406654, encodeId=1449140665449, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455277, encodeId=f53e14552e7fb, content=<a href='/topic/show?id=ce8452137f' target=_blank style='color:#2F92EE;'>#CRISPR-Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5213, encryptionId=ce8452137f, topicName=CRISPR-Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8505649833, createdName=guihongzh, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584375, encodeId=847215843e52e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624830, encodeId=7e4216248307c, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Jun 08 23:40:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208053, encodeId=6de320805350, content=是挺新颖的,可行性大吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Jun 08 08:04:24 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207946, encodeId=099120e946af, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Thu Jun 08 00:19:48 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 189****7206

    学习了谢谢分享。

    0

相关资讯

JCB:CRISPR-Cas9系统在活细胞中的工作机制取得重大突破

在一项新的研究中,来自美国马萨诸塞大学医学院的研究人员揭示出CRISPR-Cas9系统在活细胞中的内部工作机制的重要新细节。这一发现可能对人们利用这种强大的基因编辑工具开发治疗方法产生影响。相关研究结果发表在2016年8月29日那期Journal of Cell Biology期刊上,论文标题为“CRISPR-Cas9 nuclear dynamics and target recognition

Caribou宣布CRISPR-Cas9在DNA修复领域新近进展

最近,华人科学家张锋与美国科学家Dr. Jennifer Doudna就CRISPR技术专利之争因为一封邮件而再起波澜。令人庆幸的是,法律层面的争夺似乎并未令CRISPR技术明显受限。最近,CRISPR技术领域的先驱Caribou公司就再次发布了他们在CRISPR-Cas9研究领域的最新进展。公司的研究团队发现了CRISPR-Cas9基因编辑技术在不同细胞系中的响应模式。公司在最新进展中表示,

PNAS:在小鼠细胞中利用CRISPR-Cas9技术高效进行基因组编辑

为了利用CRISPR-Cas9基因编辑系统切割基因,人们必需设计一种与靶基因的DNA相匹配的RNA序列。大多数基因具有上百个这样的在基因组中的活性和独特性上存在差异的序列。因此,寻找最佳的序列很难通过手工实现。一种新的“CrispRGold”程序有助科学家们鉴定出最为高效的和最为特异性的RNA序列。这种程序是由德国马克斯-德尔布吕克分子医学中心科学家Klaus Rajewsky教授领导的一个研究团

Cell再发关闭CRISPR-Cas9新方法

12 月 8 日,在 Cell 发表的一项研究中,研究人员发现了CRISPR - Cas9活性的第一个已知的“关闭开关”。最近一个研究团队又发现了一种关闭CRISPR-Cas9的新方法,解决了CRISPR-Cas9基因编辑方法的潜在问题。团队利用噬菌体蛋白,允许更精确的基因编辑,并给予研究人员停用整个系统的可操作性。详情已经发表在12 月 29 日的 Cell 杂志上。CRISPR-Cas9 是科

利用 CRISPR-Cas9 技术让小鼠重见光明

据估计,65 岁以上有十分之一的老年人患有这种症状,并且随着老龄化的加剧这种疾病将会越来越多。AMD 在白种人中很常见,它会导致视觉扭曲和盲点。韩国基础科学研究所 (IBS) 基因组工程中心的科学家报告,他们使用 CRISPR-Cas9 技术在活体小鼠的某个支持视网膜的组织层进行“基因手术”。该研究发表在《Genome Research》上,将基础研究和小鼠模型应用结合在一起。

Nature:重磅!首次利用CRISPR-Cas9对非分裂细胞进行基因编辑

在一项新的研究中,来自美国沙克研究所的研究人员发现基因编辑的圣杯---首次能够在基因组的靶位点上将DNA插入到非分裂细胞(non-dividing cell)中,其中非分裂细胞占成年器官和组织中的大多数。他们证实这种技术能够部分恢复失明的啮齿类动物的视觉反应。它将为基础研究和多种治疗视网膜疾病、心脏疾病和神经疾病等疾病的方法打开新的途径。相关研究结果于2016年11月16日在线发表